| Autor: |
Melo GC; State University of Health Sciences of Alagoas, Maceió, Brazil., Carvalho ACA; State University of Health Sciences of Alagoas, Maceió, Brazil.; Investigative Pathology Laboratory, Federal University of Sergipe, Aracaju, Brazil.; Cesmac University Center, Maceió, Alagoas, Brazil., Mendes MLT; Investigative Pathology Laboratory, Federal University of Sergipe, Aracaju, Brazil., do Nascimento RO; Cesmac University Center, Maceió, Alagoas, Brazil., de Araújo KCGM; Department of Medicine, Federal University of Sergipe, Aracaju, Brazil., Tanajura DM; Investigative Pathology Laboratory, Federal University of Sergipe, Aracaju, Brazil., Santos VS; Centre for Epidemiology and Public Health, Federal University of Alagoas, Arapiraca, Brazil., Martins-Filho PR; Investigative Pathology Laboratory, Federal University of Sergipe, Aracaju, Brazil. |
| Abstrakt: |
HIV infection causes a constant activation of the immune system and contributes to an enhanced systemic pro-inflammatory cytokine milieu, which has been associated with premature aging and frailty. We performed a systematic review and meta-analysis to analyze whether the HIV-1 RNA load, CD4+ T-lymphocyte counts and exposure to HAART in HIV-positive subjects are associated with frailty phenotype. Searches were performed in PubMed, SCOPUS, Lilacs, Web of Science, Google Scholar, and OpenThesis databases. We used the odds ratio as a measure of the association. We used either a fixed or random-effects model to pool the results of individual studies depending on the presence of heterogeneity. Eleven studies were included in the review. Data from 8035 HIV-positive subjects were analyzed; 2413 of the subjects had viral load detectable, 981 had a CD4T-cell count <350 cells/μL, and 1342 had HAART exposure information. We found an association between frailty and CD4T-cell count <350 cells/μL (OR 2.68, CI 95% 1.68-4.26, I 2 = 46%), HIV-1 RNA load detectable (OR 1.71, CI 95% 1.38-2.12, I 2 = 0%), and protease inhibitor-containing HAART regimen (OR 2.21, CI 95% 1.26-3.89, I 2 = 0%). Further studies are necessary to evaluate the effects of other factors on the development of clinical features related to frailty. |
